Company intelligence / Profile preview

Chelsea Therapeutics International, Ltd.

Charlotte, North Carolina, United Statesorpha.net ↗

Ownership: Private
Development stage: Commercial

Overview

Chelsea Therapeutics developed NORTHERA (droxidopa), which was FDA-approved in February 2014 for the treatment of symptomatic neurogenic orthostatic hypotension (NOH) in adults with primary autonomic failure, dopamine beta hydroxylase deficiency, and non-diabetic autonomic neuropathy

Therapeutic areas: DermatologyImmunologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

droxidopa

Commercial

Indications: Neurogenic orthostatic hypotension

Partnerships

Dainippon Sumitomo Pharma Co., Ltd. (acquired global development and commercialization rights to droxidopa from them in 2006, excluding Japan, Korea, China and Taiwan)

Beyond the preview

Go deeper on Chelsea Therapeutics International, Ltd..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Chelsea Therapeutics International, Ltd..

Explore the full profile